Monitor the progress of the Phase 2a clinical trial for STAR-LLD-OCR in high-risk multiple myeloma and the Phase 1 study in CLL, as these are critical milestones for the company's development. Also, watch for any updates on the partnership with Haisco in China, as this could provide future revenue potential.
Executive Summary
Starton Holdings, Inc. is a clinical-stage biotech company developing continuous delivery systems for generic versions of cancer drugs, primarily focusing on lenalidomide (STAR-LLD) for multiple myeloma and chronic lymphocytic leukemia. The company is conducting clinical trials and has secured a development and commercialization license with Haisco in China. The IPO proceeds will fund ongoing clinical development, but the company faces significant risks including substantial losses, lack of revenue, and uncertain regulatory approval timelines.
Key Financial Metrics
Key Facts
- Company is a clinical-stage biotech focused on continuous delivery systems for cancer drugs, primarily lenalidomide (STAR-LLD).
- Has completed a Phase 1b clinical trial for STAR-LLD-SC in multiple myeloma with positive interim data showing all six patients achieved partial response or better.
- Plans to use IPO proceeds of approximately $37.2 million to fund Phase 2 trials for STAR-LLD-OCR in multiple myeloma and a Phase 1 study in CLL.
- Company has a development and commercialization license agreement with Haisco Pharmaceutical Group for the Chinese market, including a $1 million upfront payment and potential milestone payments.
- Company has incurred significant losses, with a net loss of $9.5 million for the year ended March 31, 2025, and has a history of operating losses since inception.
- The company's auditor has expressed substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flow.
Financial Impact
The company expects the IPO to raise approximately $37.2 million in net proceeds, which will fund operations through 2026.
Risk Factors
- The company has a history of significant losses and negative cash flow, raising substantial doubt about its ability to continue as a going concern.
- The company's success is highly dependent on the successful development and regulatory approval of its lead product candidates, which is uncertain and could take many years.
- The company faces intense competition from other pharmaceutical companies and may not be able to commercialize its products successfully.
- The company's intellectual property may be challenged, and it may not be able to protect its proprietary technology effectively.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001213900-26-027771 |
| Document: ea022540510ex10-13.htm | 0001213900-26-027771 |
| Document: ea022540510ex3-4.htm | 0001213900-26-027771 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers